Cutler Group’s Akero Therapeutics AKRO Stock Holding History

Cutler Group’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$15K	Buy	600 +300	+100%	+$7.21K	﹤0.01%	1103
2023 Q4	$7K	Buy	+300	New	+$5.92K	﹤0.01%	2549
2022 Q4	–	Sell	-100	Closed	-$4.29K	–	4313
2022 Q3	$3K	Buy	+100	New	+$1.53K	﹤0.01%	3894
2021 Q2	–	Sell	-800	Closed	-$23K	–	5603
2021 Q1	$23K	Buy	+800	New	+$24.2K	﹤0.01%	3081
2020 Q4	–	Sell	-500	Closed	-$15K	–	4732
2020 Q3	$15K	Sell	500 -400	-44%	-$14K	﹤0.01%	2676
2020 Q2	$22K	Buy	900 +600	+200%	+$13.7K	﹤0.01%	2298
2020 Q1	$6K	Buy	+300	New	+$6.43K	﹤0.01%	2960

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Cutler Group's AKRO Position: Q1 2024 in Review

Cutler Group increased its Akero Therapeutics (AKRO) stake by 100% in Q1 2024, buying an estimated $7.21K and bringing the position to 600 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #1103.

Cutler Group first reported a position in AKRO in Q1 2020 and has held it in 7 quarters since. The position peaked at $23K in Q1 2021. 173 funds tracked by Wall St. Rank hold AKRO as of Q1 2024.

Cutler Group held 600 shares of Akero Therapeutics worth $15K as of Q1 2024.
Cutler Group bought 300 Akero Therapeutics shares in Q1 2024, an estimated $7.21K.
Akero Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1103 holding.
Cutler Group first reported a position in Akero Therapeutics in Q1 2020 and has held it in 7 quarters since.
Cutler Group's Akero Therapeutics position peaked at $23K in Q1 2021.
173 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.